Christopher James Frankenfield
Chief Financial Officer · Xilio Therapeutics, Inc.
- 2025
- Jan 5, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher James Frankenfield files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GILEAD SCIENCES, INC. - $2.00M in XLO purchases and sales in the last 12 months
- James Samuel Shannon - $44K in XLO purchases and sales in the last 12 months
- Kevin M. Brennan - $1K in XLO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher James Frankenfield?
Christopher James Frankenfield is a corporate insider, tracked as Chief Financial Officer of Xilio Therapeutics, Inc. (XLO). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Christopher James Frankenfield last file a Form 4?
The most recent primary Form 4 on record is dated 5 January 2026, one of 2 filings going back to 2025.
Has Christopher James Frankenfield been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($5K) across all tracked filings.
